NICE Gives OK To Roche's Rozlytrek
Second Histology-Independent Drug To Win Backing
Executive Summary
Patients in England with NTRK fusion-positive solid tumors will now have access to Rozlytrek, the second cancer treatment that can be used to treat tumors regardless of where in the body they originated.